Source: Emerald Health Therapeutics, Inc.
Emerald Health
Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) has announced that in
accordance with TSX Venture Exchange Policy 2.5, the Company has met the
requirements for and been upgraded to a Tier 1 company.
The
TSX Venture Exchange classifies issuers as “Tier 1” or “Tier 2” based
on standards regarding historical financial performance, stage of
development, and financial resources. Tier 1 is the highest tier of the
TSX-V and is reserved for more advanced issuers with greater financial
resources. Tier 1 issuers benefit from less stringent filing
requirements.
“Our team has been working
diligently to meet our stated cannabis production scaling objectives,
progress our product innovation strategy, and advance a differentiating
marketing plan. In conjunction with these efforts our valuation and
financial resources have been increasing and we are pleased that our
accomplishments have allowed us to attain a higher listing status on the
TSX Venture Exchange,” said Chris Wagner, CEO of Emerald Health
Therapeutics.
About Emerald Health Therapeutics
Emerald
Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through
Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary
and Licensed Producer under Canada’s Access to Cannabis for Medical
Purposes Regulations. Through Botanicals, Emerald is authorized to
produce and sell dried medical cannabis flower and medical cannabis oil.
It currently operates an indoor facility in Victoria, BC, and is
building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with
expansion potential to 1 million s.f. to serve the anticipated legal
Canadian adult-use cannabis market starting in 2018. Emerald also owns
50% of Pure Sunfarms Inc., a partnership with Village Farms
International Inc. that is converting an existing 1.1 million s.f.
greenhouse in Delta, BC from growing tomatoes to growing cannabis.
Emerald’s team is highly experienced in life sciences, product
development and large-scale agribusiness. Emerald is part of the Emerald Health group,
which is broadly focused on developing pharmaceutical, botanical and
nutraceutical products designed to provide wellness and medical benefits
by interacting with the human body’s endocannabinoid system.
No comments:
Post a Comment